SAR405: Selective ATP-Competitive Vps34 Inhibitor for Advanced Autophagy Research

Principle Overview: Unraveling Autophagy with SAR405

Autophagy—a tightly regulated cellular process responsible for degrading and recycling cytoplasmic components—has emerged as a pivotal mechanism in cancer, neurodegeneration, and metabolic disease research. At the heart of the autophagic machinery lies the class III phosphoinositide 3-kinase Vps34, which orchestrates autophagosome formation and vesicle trafficking. SAR405 is a highly potent, selective ATP-competitive Vps34 inhibitor (Kd = 1.5 nM; IC₅₀ = 1 nM), designed to dissect the intricacies of autophagy inhibition and vesicle trafficking modulation with unparalleled precision. Unlike traditional PI3K inhibitors, SAR405 demonstrates exquisite selectivity, sparing class I/II PI3Ks and mTOR even at 10 μM, thereby minimizing off-target effects and facilitating more interpretable data in cell-based and in vivo studies.

Recent research, including the paradigm-shifting study by Park et al. (2023), has redefined our understanding of AMPK-ULK1 signaling in autophagy initiation. These insights heighten the importance of tools like SAR405, which can interrogate the Vps34 kinase signaling pathway with specificity, enabling researchers to decouple the direct effects of phosphoinositide 3-kinase class III inhibition from broader cellular stress responses.

Experimental Workflow: Optimizing SAR405 Use in Autophagy and Vesicle Trafficking Studies

1. Compound Preparation and Storage

• Solubility: SAR405 is highly soluble in DMSO (>10 mM), moderately soluble in ethanol (with ultrasonic assistance), and insoluble in water. Prepare concentrated stock solutions in DMSO for consistent dosing.
• Storage: Store SAR405 stock solutions at <-20°C for several months. Avoid repeated freeze-thaw cycles and long-term storage of diluted solutions to maintain compound integrity.

2. Cell-Based Assays: Protocol Enhancements

1. Cell Line Selection: SAR405 has been validated in GFP-LC3 HeLa and H1299 cells for monitoring autophagosome formation blockade. It is also compatible with a range of cancer and neurodegenerative disease models.
2. Treatment Regimen: Typical working concentrations range from 10 nM to 1 μM, with observable lysosome function impairment and autophagy inhibition at as low as 10 nM.
3. Assay Readouts: Quantify autophagy inhibition using LC3-II accumulation (by immunoblotting), fluorescence imaging of GFP-LC3 puncta, and assessment of p62/SQSTM1 stability. For vesicle trafficking modulation, monitor endosome-lysosome dynamics using LysoTracker or cathepsin D maturation assays.
4. Synergistic Studies: Combine SAR405 with mTOR inhibitors (e.g., everolimus) to assess additive or synergistic effects on autophagosome formation blockade, as SAR405 disrupts the Vps34-dependent node, complementing mTORC1 inhibition.

3. Data-Driven Insights

• In cellular assays, SAR405 induces the accumulation of swollen late endosome-lysosomes—a hallmark of vesicle trafficking modulation—within 4–8 hours of treatment.
• Quantitative imaging reveals >80% reduction in autophagosome numbers in treated cultures compared with vehicle controls, confirming robust autophagy inhibition.
• SAR405 does not impair cell viability at concentrations effective for Vps34 inhibition, minimizing confounding toxicity.

Advanced Applications and Comparative Advantages

Dissecting Autophagy in Cancer and Neurodegenerative Disease Models

SAR405 is a transformative tool for interrogating the mechanistic underpinnings of autophagy and vesicle trafficking in disease-relevant systems. In cancer research, the ability to precisely block the Vps34 kinase signaling pathway enables the evaluation of autophagy’s dual roles—tumor suppression versus tumor promotion—across tumor types and treatment contexts. In neurodegenerative disease models, SAR405 facilitates studies on lysosome function impairment and protein aggregate clearance, providing insights into pathologies like Parkinson’s and Alzheimer’s disease.

SAR405’s selectivity profile stands in stark contrast to earlier-generation PI3K inhibitors, which frequently confounded results via mTOR or class I/II PI3K inhibition. This unique specificity is highlighted in the article "SAR405 and the Next Frontier in Autophagy Research", which underscores its superiority in mechanistic and translational studies. Furthermore, as discussed in "SAR405: Selective ATP-Competitive Vps34 Inhibitor for Autophagy Research", the compound’s robust performance enables researchers to revisit and refine autophagy paradigms, particularly in light of the nuanced AMPK-ULK1 regulatory network.

Complementing Emerging Signaling Insights

The fine-grained control over autophagosome formation blockade afforded by SAR405 is especially pertinent given recent findings that AMPK can inhibit, rather than promote, ULK1 activity and autophagy induction. This revelation, detailed by Park et al. (2023), necessitates tools that can selectively interrogate Vps34-dependent steps, independent of upstream AMPK or mTOR modulation. SAR405’s capacity to target the Vps34 node directly makes it invaluable for teasing apart these regulatory layers. The article "SAR405 and the New Paradigm of Vps34 Inhibition in Autophagy" further explores this intersection, illustrating how SAR405 complements evolving mechanistic models.

Troubleshooting and Optimization Tips

• Solubility Challenges: If precipitation occurs after dilution, ensure the stock solution is completely dissolved in DMSO and add it to media with thorough mixing. Avoid exceeding 0.1% DMSO in final working solutions.
• Assay Sensitivity: For subtle effects on vesicle trafficking or autophagy inhibition, extend incubation times (up to 24 hours) or use higher-sensitivity readouts such as high-content imaging or quantitative proteomics.
• Compound Stability: Prepare fresh working solutions immediately before use. Long-term storage of diluted SAR405 (e.g., in aqueous buffers) leads to loss of potency.
• Off-Target Monitoring: Although SAR405 is highly selective, validate findings with genetic controls (e.g., Vps34 knockdown) to rule out cell line-specific artifacts.
• Synergy Experiments: For combination studies with mTOR inhibitors or other autophagy modulators, optimize dosing schedules to avoid overlapping cytotoxicity or confounding pathway crosstalk.

Future Outlook: SAR405 and the Next Generation of Autophagy Research

SAR405’s emergence as a selective ATP-competitive Vps34 inhibitor heralds a new era of precision in autophagy and vesicle trafficking research. Its compatibility with advanced experimental platforms—including CRISPR-based genetic screens, live-cell imaging, and multi-omics profiling—positions it at the forefront of disease model interrogation. As our understanding of regulatory networks like AMPK-ULK1 deepens, SAR405 will enable researchers to delineate the context-dependent roles of autophagy, unmasking novel therapeutic vulnerabilities in cancer and neurodegenerative disorders.

The role of SAR405 as a pharmacological probe is poised to expand further, with ongoing studies integrating it into combinatorial regimens and systems biology frameworks. Its robust selectivity, nanomolar potency, and ease of use make it a staple in the experimental arsenal. For researchers seeking to leverage the latest insights and tools, sourcing SAR405 from trusted suppliers such as APExBIO ensures consistent quality and support for cutting-edge projects.

For additional context and advanced strategies, see "SAR405: Redefining Vps34 Inhibition for Precision Autophagy Research", which extends on SAR405’s role in next-generation disease models and highlights its integration with emerging AMPK-ULK1 signaling discoveries.

---

Explore more about SAR405’s specifications, ordering information, and application notes at the official product page.